US 12,233,067 B2
Topical treatment of vitiligo by a JAK inhibitor
Kathleen Butler, Wilmington, DE (US); Jim Lee, Devon, PA (US); Kang Sun, Wallingford, PA (US); Fiona Kuo, West Chester, PA (US); and Michael Howell, Kennett Square, PA (US)
Assigned to Incyte Corporation, Wilmington, DE (US)
Filed by Incyte Corporation, Wilmington, DE (US)
Filed on Dec. 8, 2022, as Appl. No. 18/077,315.
Application 18/077,315 is a continuation of application No. 16/897,923, filed on Jun. 10, 2020, granted, now 11,602,536.
Claims priority of provisional application 62/967,879, filed on Jan. 30, 2020.
Claims priority of provisional application 62/911,845, filed on Oct. 7, 2019.
Claims priority of provisional application 62/894,496, filed on Aug. 30, 2019.
Claims priority of provisional application 62/894,581, filed on Aug. 30, 2019.
Claims priority of provisional application 62/894,541, filed on Aug. 30, 2019.
Claims priority of provisional application 62/894,564, filed on Aug. 30, 2019.
Claims priority of provisional application 62/894,514, filed on Aug. 30, 2019.
Claims priority of provisional application 62/859,506, filed on Jun. 10, 2019.
Claims priority of provisional application 62/859,601, filed on Jun. 10, 2019.
Claims priority of provisional application 62/859,495, filed on Jun. 10, 2019.
Claims priority of provisional application 62/859,584, filed on Jun. 10, 2019.
Claims priority of provisional application 62/859,532, filed on Jun. 10, 2019.
Prior Publication US 2023/0355628 A1, Nov. 9, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/519 (2006.01); A61P 17/00 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 9/107 (2006.01)
CPC A61K 31/519 (2013.01) [A61P 17/00 (2018.01); A61K 9/0014 (2013.01); A61K 9/06 (2013.01); A61K 9/107 (2013.01)] 15 Claims
 
1. A method of treating nonsegmental vitiligo in a patient, comprising:
topically administering to a depigmented skin area of the patient a pharmaceutical composition comprising about 1.5% w/w ruxolitinib, or a pharmaceutically acceptable salt thereof, on a free base basis, twice per day;
wherein:
the patient suffers from nonsegmental vitiligo with depigmented area of: (i) 0.5% or greater body surface area (BSA) on the face, (ii) 3% or greater BSA on non-facial areas, and (iii) not exceeding 10% BSA on total body area; and
the patient achieves a 75% or greater improvement in total body Vitiligo Area Scoring Index (T-VASI75).